ATDC Function in Human Pancreatic Adenocarcinoma

ATDC 在人胰腺腺癌中的功能

基本信息

  • 批准号:
    9041530
  • 负责人:
  • 金额:
    $ 36.81万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2008
  • 资助国家:
    美国
  • 起止时间:
    2008-09-01 至 2020-03-31
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant): Pancreatic adenocarcinoma (PDA) is a deadly disease characterized by late diagnosis, aggressive invasion of surrounding tissues, and early metastasis. Patients with stage 1A disease have a 30% 5 year survival rate following resection, highlighting that PDA metastasizes early in patients, however, the molecular mechanisms driving early metastasis in PDA are not understood. We have recently found that the majority of human pancreatic adenocarcinomas have elevated expression of the Ataxia-Telangiectasia Group D Associated (ATDC) gene and that ATDC has an oncogenic function in pancreatic cancer through Wnt pathway activation and -catenin stabilization. Using newly created genetically engineered mouse models of pancreatic cancer, we have now identified a previously unknown role for ATDC in pancreatic cancer, where ATDC is upregulated during the early PanIN stage of tumorigenesis, and in the presence of oncogenic Kras, accelerates PanIN progression and the development of invasive and metastatic tumors. ATDC upregulates CD44 in mouse and human PanIN lesions through a -catenin-induced mechanism, resulting in the induction of an epithelial to mesenchymal transition (EMT) phenotype characterized by expression of Zeb1 and Snail1. Knockdown of ATDC blocks invasion in mouse and human PDA cells and this effect is mediated through -catenin and CD44. In this proposal, we hypothesize that ATDC is a proximal regulator of EMT and drives progression and metastasis of pancreatic cancer, thus serving as an important therapeutic target. To dissect the role of ATDC in pancreatic cancer, we will: 1) investigate the role of ATDC in pancreatic tumorigenesis using novel genetically engineered mouse models; 2) characterize the molecular mechanisms by which ATDC induces an invasive phenotype in PDA; and 3) determine the mechanism of ATDC upregulation in pancreatic cancer.
 描述(由申请人提供):胰腺腺癌(PDA)是一种致命的疾病,其特征是诊断较晚,侵袭周围组织,早期转移。1A期疾病患者切除后的5年生存率为30%,这突出表明PDA在患者中早期转移,然而,驱动PDA早期转移的分子机制尚不清楚。我们最近发现,大多数人胰腺癌具有升高的共济失调-毛细血管扩张D组相关(ATDC)基因表达,并且ATDC通过Wnt途径激活和β-连环蛋白稳定在胰腺癌中具有致癌功能。使用新创建的胰腺癌基因工程小鼠模型,我们现在已经确定了ATDC在胰腺癌中以前未知的作用,其中ATDC在肿瘤发生的早期PanIN阶段上调,并且在致癌Kras的存在下,加速PanIN进展以及侵袭性和转移性肿瘤的发展。ATDC通过β-连环蛋白诱导的机制上调小鼠和人PanIN病变中的CD 44,导致诱导以Zeb 1和Snail 1表达为特征的上皮向间质转化(EMT)表型。ATDC的敲低阻断小鼠和人PDA细胞中的侵袭,并且该作用通过β-连环蛋白和CD 44介导。在这个提议中,我们假设ATDC是EMT的近端调节因子,并驱动胰腺癌的进展和转移,从而作为一个重要的治疗靶点。为了剖析ATDC在胰腺癌中的作用,我们将:1)使用新型基因工程小鼠模型研究ATDC在胰腺肿瘤发生中的作用; 2)表征ATDC诱导PDA中侵袭性表型的分子机制;和3)确定胰腺癌中ATDC上调的机制。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DIANE M SIMEONE其他文献

DIANE M SIMEONE的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DIANE M SIMEONE', 18)}}的其他基金

Biomarker Validation in Pancreatic Cystic Neoplasms
胰腺囊性肿瘤的生物标志物验证
  • 批准号:
    10722347
  • 财政年份:
    2023
  • 资助金额:
    $ 36.81万
  • 项目类别:
POLQ Synthetic Lethality in HR-Deficient Pancreatic Adenocarcinoma
HR 缺陷型胰腺癌中的 POLQ 综合致死率
  • 批准号:
    10218126
  • 财政年份:
    2020
  • 资助金额:
    $ 36.81万
  • 项目类别:
POLQ Synthetic Lethality in HR-Deficient Pancreatic Adenocarcinoma
HR 缺陷型胰腺癌中的 POLQ 综合致死率
  • 批准号:
    10442427
  • 财政年份:
    2020
  • 资助金额:
    $ 36.81万
  • 项目类别:
POLQ Synthetic Lethality in HR-Deficient Pancreatic Adenocarcinoma
HR 缺陷型胰腺癌中的 POLQ 综合致死率
  • 批准号:
    10656484
  • 财政年份:
    2020
  • 资助金额:
    $ 36.81万
  • 项目类别:
2015 Pancreatic Diseases Gordon Research Conference
2015年胰腺疾病戈登研究会议
  • 批准号:
    8970783
  • 财政年份:
    2015
  • 资助金额:
    $ 36.81万
  • 项目类别:
Oncogenic Function of ATDC in Bladder Cancer
ATDC 在膀胱癌中的致癌功能
  • 批准号:
    9491077
  • 财政年份:
    2014
  • 资助金额:
    $ 36.81万
  • 项目类别:
Oncogenic Function of ATDC in Bladder Cancer
ATDC 在膀胱癌中的致癌功能
  • 批准号:
    9017959
  • 财政年份:
    2014
  • 资助金额:
    $ 36.81万
  • 项目类别:
Project 3: lncRNA SNHG1 and ATG7 in Basal-subtype Muscle-invasive Bladder Tumorigenesis
项目3:lncRNA SNHG1和ATG7在基底亚型肌侵袭性膀胱肿瘤发生中的作用
  • 批准号:
    10661067
  • 财政年份:
    2013
  • 资助金额:
    $ 36.81万
  • 项目类别:
Project 3: lncRNA SNHG1 and ATG7 in Basal-subtype Muscle-invasive Bladder Tumorigenesis
项目3:lncRNA SNHG1和ATG7在基底亚型肌侵袭性膀胱肿瘤发生中的作用
  • 批准号:
    10229414
  • 财政年份:
    2013
  • 资助金额:
    $ 36.81万
  • 项目类别:
Project 3: lncRNA SNHG1 and ATG7 in Basal-subtype Muscle-invasive Bladder Tumorigenesis
项目3:lncRNA SNHG1和ATG7在基底亚型肌侵袭性膀胱肿瘤发生中的作用
  • 批准号:
    10455731
  • 财政年份:
    2013
  • 资助金额:
    $ 36.81万
  • 项目类别:

相似海外基金

Assessing The Impact of Heparanase and NDST2 Expression on Non-Small Cell Lung Adenocarcinoma Cell Motility
评估乙酰肝素酶和 NDST2 表达对非小细胞肺腺癌细胞运动的影响
  • 批准号:
    449570
  • 财政年份:
    2020
  • 资助金额:
    $ 36.81万
  • 项目类别:
    Studentship Programs
Analysis of cancer metastasis and invasion mechanism using a new lung adenocarcinoma cell line.
使用新的肺​​腺癌细胞系分析癌症转移和侵袭机制。
  • 批准号:
    16K10689
  • 财政年份:
    2016
  • 资助金额:
    $ 36.81万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Acquisition strategy of tumor-specific markers using established micropapillary pattern pulmonary adenocarcinoma cell line
使用已建立的微乳头模式肺腺癌细胞系获取肿瘤特异性标志物的策略
  • 批准号:
    26460441
  • 财政年份:
    2014
  • 资助金额:
    $ 36.81万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
The antibetic drug metformin inhibits esophageal adenocarcinoma cell proliferation in vitro and in vivo.
抗生素药物二甲双胍在体外和体内抑制食管腺癌细胞增殖。
  • 批准号:
    25860540
  • 财政年份:
    2013
  • 资助金额:
    $ 36.81万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
The cell permeable peptide inhibits pancreatic ductal adenocarcinoma cell proliferations and can be used as the molecular targeting dru
细胞通透肽抑制胰腺导管腺癌细胞增殖,可作为分子靶向药物
  • 批准号:
    25461969
  • 财政年份:
    2013
  • 资助金额:
    $ 36.81万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Basic Research for elucidation of chemo-resistance in mucinous adenocarcinoma cell.
阐明粘液腺癌细胞化疗耐药性的基础研究。
  • 批准号:
    22791532
  • 财政年份:
    2010
  • 资助金额:
    $ 36.81万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
TAS::75 0849::TAS IN THIS PHASE I SBIR THE BREAST CANCER ADENOCARCINOMA CELL LI
TAS::75 0849::TAS 在这一阶段 I SBIR 乳腺癌腺癌细胞 LI
  • 批准号:
    8164743
  • 财政年份:
    2010
  • 资助金额:
    $ 36.81万
  • 项目类别:
Role of Endothelin-1 in osteoblastic bone metastasis produced by a human lung adenocarcinoma cell line
Endothelin-1 在人肺腺癌细胞系产生的成骨细胞骨转移中的作用
  • 批准号:
    19790127
  • 财政年份:
    2007
  • 资助金额:
    $ 36.81万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
CONNEXIN 43 EXPRESSION IN ADENOCARCINOMA CELL LINE
连接蛋白 43 在腺癌细胞系中的表达
  • 批准号:
    6972483
  • 财政年份:
    2004
  • 资助金额:
    $ 36.81万
  • 项目类别:
The mechanisms of highly metastetic capasity in highly metastatic subpopulations of lung adenocarcinoma cell line and these clinical applications
肺腺癌细胞系高转移亚群的高转移能力机制及临床应用
  • 批准号:
    15590831
  • 财政年份:
    2003
  • 资助金额:
    $ 36.81万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了